Coronary drug project
High Density Lipoprotein Microchapters
Coronary drug project On the Web
American Roentgen Ray Society Images of Coronary drug project
Coronary Drug Project
To determine whether regular administration of lipid modifying drugs (clofibrate, nicotinic acid, estrogen, dextrothyroxine) to men with a documented myocardial infarction would result in significant reduction in total mortality over a five year period. Secondarily, to determine whether the degree to which these drugs changed serum lipids was correlated with any effect on mortality and morbidity rates; to gain further information on the long-term prognosis of myocardial infarction (by studying the control group as intensively as the treatment group); to acquire further experience and knowledge concerning the techniques and methodology of long-term clinical trials; to determine, in a substudy, the effectiveness of aspirin, a platelet inhibitor, in reducing recurrences of myocardial infarction.
National Heart, Lung, and Blood Institute (NHLBI)
|Start Date||April 1965|
|End Date||March 1985|
The previous information was derived from ClinicalTrials.gov on 08/18/2014 using the identification number NCT00000482.
|Study Phase||Phase 3|
|Condition||Cardiovascular diseases; coronary disease; heart diseases; myocardial infarction; myocardial ischemia|
Drug: clofibrate clofibrate
|Population Size||8,341 subjects|
The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00000482.
Men, ages 30-64, three months beyond most recent myocardial infarction